BBA
CRNX

Baker Bros. Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Baker Bros. Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88M Hold
2,351,465
– – 0.44% 29
2026
Q1 		$85.4M Buy
2,351,465
+702,596
+43% +$31.4M 0.49% 26
2025
Q4 		$76.8M Buy
1,648,869
+1,368,869
+489% +$60.9M 0.45% 31
2025
Q3 		$11.7M Hold
280,000
– – 0.08% 63
2025
Q2 		$8.05M Buy
+280,000
New +$8.65M 0.08% 57
2024
Q4 		– Sell
-103,927
Closed -$5.31M – 99
2024
Q3 		$5.31M Hold
103,927
– – 0.06% 66
2024
Q2 		$4.65M Buy
+103,927
New +$4.8M 0.06% 68
2022
Q4 		– Sell
-735,716
Closed -$14.4M – 117
2022
Q3 		$14.4M Sell
735,716
-91,764
-11% -$1.87M 0.09% 55
2022
Q2 		$15.4M Hold
827,480
– – 0.09% 56
2022
Q1 		$18.2M Hold
827,480
– – 0.1% 56
2021
Q4 		$23.5M Sell
827,480
-93,176
-10% -$2.3M 0.11% 53
2021
Q3 		$19.4M Hold
920,656
– – 0.09% 63
2021
Q2 		$17.4M Buy
920,656
+304,136
+49% +$5.34M 0.08% 65
2021
Q1 		$9.42M Hold
616,520
– – 0.04% 78
2020
Q4 		$8.7M Buy
616,520
+314,200
+104% +$4.38M 0.03% 78
2020
Q3 		$4.74M Sell
302,320
-15,537
-5% -$238K 0.02% 82
2020
Q2 		$5.57M Buy
317,857
+142,857
+82% +$2.44M 0.02% 78
2020
Q1 		$2.57M Hold
175,000
– – 0.02% 83
2019
Q4 		$4.39M Hold
175,000
– – 0.02% 74
2019
Q3 		$2.63M Buy
175,000
+42,015
+32% +$817K 0.02% 83
2019
Q2 		$3.33M Buy
132,985
+1,735
+1% +$43K 0.02% 71
2019
Q1 		$2.99M Hold
131,250
– – 0.02% 71
2018
Q4 		$3.94M Hold
131,250
– – 0.03% 59
2018
Q3 		$3.76M Buy
+131,250
New +$3.9M 0.02% 77

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baker Bros. Advisors's CRNX Position: Q2 2026 in Review

Baker Bros. Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 2,351,465 shares worth $88M. The position accounts for 0.44% of the portfolio, ranked #29.

Baker Bros. Advisors first reported a position in CRNX in Q3 2018 and has held it in 24 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Baker Bros. Advisors held 2,351,465 shares of Crinetics Pharmaceuticals worth $88M as of Q2 2026.
  • Baker Bros. Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up 0.44% of Baker Bros. Advisors's portfolio in Q2 2026, its #29 holding.
  • Baker Bros. Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 24 quarters since.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.